Side-effect lists can make every symptom look equally alarming. A more useful approach is to learn what your own product label says and agree with your clinician on how to get help.
This guide summarizes selected warnings from approved tirzepatide labels. It is not a complete safety review, and it cannot tell you whether a symptom is caused by your medicine. Compounded preparations have additional uncertainties.
Ask for a contact plan before treatment starts. Severe symptoms need medical attention, not an online dose adjustment.
Common does not mean you must put up with it
Nausea, diarrhea, vomiting, constipation, and abdominal discomfort appear in tirzepatide labeling. Tell your clinician about symptoms that persist, worsen, or interfere with eating and drinking. Describe when they started, how often they happen, and what you can keep down.
Do not increase, skip, or repeat a dose based on a general article. Your prescriber needs to consider the actual product and your circumstances. Our appointment checklist includes a place to ask who handles between-visit problems.
Sources: Lilly: Zepbound prescribing information · Lilly: Mounjaro prescribing information
Know the symptoms that need prompt attention
The labels describe pancreatitis, gallbladder problems, dehydration-related kidney injury, and serious allergic reactions among the important risks. Severe or persistent abdominal pain, particularly with vomiting or pain extending to the back, needs prompt medical assessment. Inability to keep fluids down also warrants timely help.
Trouble breathing, swelling of the face or throat, fainting, or other signs of a severe allergic reaction require emergency care. Call 911 for a medical emergency. Do not wait for a routine portal response. Your clinician should explain the full warning list and the action to take for your prescription.
Sources: Lilly: Zepbound prescribing information · Lilly: Mounjaro prescribing information
Your history changes the conversation
Approved tirzepatide labels carry a boxed warning about thyroid C-cell tumors observed in rats; whether this occurs in humans is unknown. They contraindicate use with a personal or family history of medullary thyroid carcinoma or MEN2, as well as certain serious hypersensitivity histories.
Discuss severe stomach-emptying problems, pregnancy or pregnancy plans, and medicines such as insulin or sulfonylureas. Tell the team performing any procedure with anesthesia or deep sedation that you take tirzepatide. They need to make an individualized plan. This is a selected list, not a screening questionnaire.
Sources: Lilly: Zepbound prescribing information · Lilly: Mounjaro prescribing information
Make the safety plan practical
Write down the clinical phone number, usual response time, and after-hours route. Ask what information to have ready when you call, including the label, dose instructions, and timing of symptoms. If the dispensing pharmacy changes, ask the pharmacist to review the new label with you.
Our compounding guide explains why concentrations and instructions deserve particular attention with compounded products. The protein and strength article discusses maintaining nutrition without dismissing significant symptoms as part of the process.
Sources: FDA: Concerns with unapproved GLP-1 drugs · FDA: Managing medicine benefits and risks
The source shelf
- Lilly: Zepbound prescribing information
Current approved-product label, revised August 2026; does not establish equivalence of compounded preparations.
- Lilly: Mounjaro prescribing information
Product-specific diabetes indications and safety information. Not an interchangeable label for compounded tirzepatide.
- FDA: Concerns with unapproved GLP-1 drugs
Compounding, fraudulent labels, dosing errors and the limits of adverse-event reports. Checked September 23, 2026.
- FDA: Managing medicine benefits and risks
General questions for clinical decision-making and medication follow-up.
